JOHNSON & JOHNSON·4

Apr 27, 5:43 PM ET

Doudna Jennifer A 4

Research Summary

AI-generated summary

Updated

Johnson & Johnson Director Jennifer Doudna Receives 975 DSUs

What Happened
Jennifer A. Doudna, a member of the Johnson & Johnson (JNJ) board, was granted 975 Deferred Share Units (DSUs) on April 23, 2026. The Form 4 reports the grant as an award (code A) with a reported price of $0.00 because DSUs are a deferred/cash-settled derivative rather than immediate stock issuance. These DSUs represent the right to receive cash equal to the fair market value of 975 JNJ shares when they are settled.

Key Details

  • Transaction date: 2026-04-23; Form 4 filed: 2026-04-27 (filed timely).
  • Reported transaction: 975 DSUs acquired (award), reported at $0.00 per unit on the Form 4 (derivative).
  • Shares owned after transaction: Not specified in this filing.
  • Footnotes: F1 — DSUs granted under the Issuer’s Amended and Restated Deferred Fee Plan for Directors and will be settled in cash upon termination of directorship (each DSU equals the fair market value of one share at settlement). F2 — Dividend equivalent rights on DSUs were included and accrued.
  • Transaction code: A = Award/Grant (derivative); not an open-market purchase or sale.

Context
DSUs are a common form of director compensation that defer value until a director leaves the board; they do not convey immediate stock ownership or signal a buy/sell decision. The cash settlement and dividend equivalents mean the grant tracks future JNJ share value rather than creating new shares today.